Studies have suggested that the lenvatinib boosts the effectiveness of the PD‐1 inhibitor by reversing immunosuppressive effects of vascular endothelial growth factor (VEGF) in the tumour microenvironment, thus enhancing the tumour responsiveness to the combination therapy.35, 36. This evidence concerns the gene VEGFA and neoplasm.